Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer (ENZA-p)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04419402 |
|
Recruitment Status :
Recruiting
First Posted : June 5, 2020
Last Update Posted : February 16, 2022
|
Sponsor:
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Collaborators:
National Health and Medical Research Council, Clinical Trials Centre
Prostate Cancer Research Alliance
Endocyte
Astellas Pharma Inc
Information provided by (Responsible Party):
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | June 1, 2022 |
| Estimated Study Completion Date : | June 1, 2023 |